Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 25,190 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PRE Clear all

Conditions: Premature Birth
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Female only
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Renal Cell Carcinoma
Interventions: DC vaccine, Bevacizumab, IL-2, IFN; Biological · Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Glenoid Labrum Tear
Interventions: BFR, Standard Rehabilitation; Device · Other
Lead sponsor: Andrews Research & Education Foundation; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Gulf Breeze, Florida

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 70
States / cities: Little Rock, Arkansas • Concord, California • Encino, California + 60 more

Conditions: Adhesive Capsulitis, Adhesive Capsulitis of Shoulder, Frozen Shoulder, Shoulder Frozen, Shoulder Pain, Mobility Limitation
Interventions: Kinect motion tracking system; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Wounds
Interventions: Pulse lavage treatment, Dressing changes; Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Smoking, Hookah, Waterpipe Smoking
Interventions: Flavored-Sweetened Waterpipe Tobacco, Unflavored-sweetened waterpipe tobacco, Unflavored-very low sweetened waterpipe tobacco, Flavored-very low sweetened waterpipe; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 50 Years
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Work of Breathing, Term Infant
Interventions: Work of breathing observation; Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 1 Day to 1 Week
Enrollment: 31 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Non-Hodgkin's Lymphoma
Interventions: Glofitamab, Obinutuzumab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 6
States / cities: Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more

Conditions: Primary Biliary Cholangitis
Interventions: Elafibranor, Placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 20
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Muscular Injury
Interventions: Turmeric Strength for Joint, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Interventions: Anifrolumab, Anifrolumab; Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 80 Years
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 21
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 18 more

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Neer Infrared Spectroscopy; Device
Lead sponsor: Keck School of Medicine of USC; Other
Eligibility: 1 Hour to 24 Hours
Enrollment: 50 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-melanoma Skin Cancer
Interventions: Acetaminophen; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autism Spectrum Disorder, Anesthesia, Procedural Anxiety, Sensory Processing Disorder
Interventions: Sensory adaptive environment; Other
Lead sponsor: Dayton Children's Hospital; Other
Eligibility: 3 Years to 12 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma
Interventions: 8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Sickle Cell Disease
Interventions: Defibrotide; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 6 Months to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Valhalla, New York + 1 more

Conditions: Drink Too Much, Drinking, Binge, Drunk, Drug Use, Aggression, Aggression Sexual, Peer Group, Safety Issues, Harm Reduction
Interventions: Nightlife Safety Plans (NSP), Fire Safety; Behavioral
Lead sponsor: Pacific Institute for Research and Evaluation; Other
Eligibility: 21 Years and older
Enrollment: 959 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Berkeley, California

Conditions: Jaw, Edentulous
Interventions: Overdenture treatment; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Non-small Cell Lung Cancer
Interventions: Tepotinib, Osimertinib; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 49
States / cities: Yuma, Arizona • Fountain Valley, California • Long Beach, California + 43 more

Conditions: Sebaceous Hyperplasia
Interventions: Imiquimod 5% Topical Cream; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Brain Mass
Interventions: MRI with DTI and fMRI; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV/AIDS, Adherence, Medication, Drug Use
Interventions: Text Messaging, Peer Navigation; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Seattle, Washington

Search by objective public record fields.

Precision Medicine for Preterm Birth

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Blood Flow Restriction Training Following Glenoid Labral Repair

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes

Using Kinect Motion Capture to Measure Shoulder Motion in Patients Undergoing Capsular Distension for Adhesive Capsulitis

Evaluation of the Effectiveness of Daily Pulse Lavage Therapy in Chronic Wounds

The Impact of Waterpipe Tobacco Flavors on Waterpipe Smoking Intentions, Perceptions, Patterns, and Toxicant Exposure

Work of Breathing in Term Infants

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Turmeric and Exercise-Induced Muscle Damage and Oxinflammation

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

Application of Lung Near-Infrared Spectroscopy (NIRS) in Preterm Infants

Preoperative Acetaminophen and Carbohydrate Loading

Use of an Adaptive Sensory Environment in Autism Spectrum Disorder (ASD) Patients in the Perioperative Environment

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Group-based Intervention for Club Patrons

Conventional, Overdenture and Palateless Overdenture Oral Health Impact Comparison Study

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

Functional Imaging of Cerebellar Mutism Syndrome

Interventions to Improve the HIV PrEP Cascade Among Methamphetamine Users